Hi-Tech Pharmacal (Nasdaq: HITK) is expected to report Q4 earnings on July 9. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Hi-Tech Pharmacal's revenues will expand 8.8% and EPS will contract -11.0%.

The average estimate for revenue is $66.7 million. On the bottom line, the average EPS estimate is $0.65.

Revenue details
 Last quarter, Hi-Tech Pharmacal tallied revenue of $64.3 million. GAAP reported sales were 16% higher than the prior-year quarter's $55.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, EPS came in at $0.43. GAAP EPS of $0.43 for Q3 were 46% lower than the prior-year quarter's $0.79 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 51.1%, 420 basis points worse than the prior-year quarter. Operating margin was 13.6%, much worse than the prior-year quarter. Net margin was 9.2%, much worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $240.6 million. The average EPS estimate is $2.18.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 202 members out of 216 rating the stock outperform, and 14 members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 47 give Hi-Tech Pharmacal a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hi-Tech Pharmacal is outperform, with an average price target of $39.00.